The Centers for Disease Control and Prevention estimates that the total economic burden of prescription opioid misuse alone in the United States is $78.5 billion a year, including the costs of healthcare, lost productivity, addiction treatment, and criminal justice involvement.1
Oxycodone is a semisynthetic opioid analgesic prescribed for the relief of moderate to severe pain. Oxycodone structurally resembles codeine and morphine, with similar analgesic properties and potential for addiction and abuse. Oxycodone is a DEA schedule II drug. The drug oxycodone is prescribed in controlled-release form (OXYCONTIN), or in combination with acetaminophen (PERCOCET) or with aspirin (PERCODAN).
Features & Benefits
The Emit II Plus Oxycodone assay offers 100 ng/mL and 300 ng/mL cutoffs and no cross-reactivity to structurally related compounds such as buprenorphine and hydrocodone.
- Achieve high specificity for oxycodone and oxymorphone to provide confidence for accurate results while meeting the SAMHSA requirements for oxycodone screening
- Reduce false results with an assay that has 98% agreement to LC-MS/MS for positive samples and 100% agreement for negatives.1
- Consolidate opioid testing with other Siemens Healthineers assays, enabling providers to screen patients on one trusted system
EMIT II Plus Oxycodone Assay Performance*
1Florence CS, Zhou C, Luo F, Xu L. The Economic Burden of Prescription Opioid Overdose, Abuse, and Dependence in the United States, 2013. Med Care. 2016;54(10):901-906. doi:10.1097/MLR.0000000000000625.
*Future availability cannot be guaranteed